The Brazil animal diagnostics market is expected to hit USD 287 million by 2027, owing to the rising number of companion animal ownership and increasing prevalence of infectious & parasitic diseases across the country.
Read Moreoncgnostics develops, based on proprietary epigenetic biomarkers molecular tests for reliable cancer diagnostics. This test allows reliable diagnostics of cervical cancer and its pre-stages. Now oncgnostics has raised a seven-digit Euro amount in a Series A financing round.
Read MoreIntervention Insights, Inc., a company that offers a personalized medicine service for oncologists, released a report summarizing the inaugural conference, Personalized Medicine: Promises and Perils for Community Oncology and Payers.
Read More